Keyword: Pharmaceutical Care Management Association
While Republicans are blasting Nancy Pelosi's drug plan as socialist, hospitals and insurers are finding a lot to like.
Healthcare experts weighed in on several House bills aimed at increasing transparency in the pharmaceutical supply chain at a hearing Tuesday.
Health insurers and pharmacy benefit managers aren't succeeding when it comes to drug access for autoimmune diseases, according to a new study.
The Trump administration’s plan to end legal protections for drug rebates would boost Part D premiums and federal spending, according to CBO.
Pharma CEOs went before the Senate last month, and now it’s PBMs’ turn to be on the hot seat.
PCMA released a statement calling HHS' proposed rule on prescription drug rebates for Medicare and Medicaid beneficiaries “poorly conceived."
Thanks to a bill introduced in Congress on Wednesday, drug rebates in commercial plans are on the chopping block.
The current structure of reimbursement for drugs in the U.S. is “regressive” and ultimately hurting patients, pharmaceutical executives said Tuesday.
Democrats have officially revealed a plan to let people ages 50 and over buy in to Medicare, plus more insurance news.
PBMs are hitting back against critics who blame them for rising drug prices, as the system they use to negotiate rebates hangs in the balance.